Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dalriada
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(256)
•••
Comment by GameChangerBeton Jun 25, 2021 3:10pm
213 Views
Post# 33451674

RE:RE:RE:RE:RE:RE:Dalriada

RE:RE:RE:RE:RE:RE:DalriadaThe currect cash on hand is said to cover Phase III, but keep in mind of the high probability of a deal being reached at some point between now and then, which will come with some type of upfront cash payment as part of the deal.
So yes, current cash is $70m +/- but you can include with some relative assumptions that they will be getting a cash infusion at some point before Phase III completion, further strengthening their position as they move forward. 

Straylight wrote: I believe in some of the previous conference calls Dan mentioned that they could move several other drug candidates along for about $1-2m. Of course that is a high level answer and that was probably before they got serious into negotiations for this contract.

Now how drugs this covers, how far it takes them, what the contract value is; all things that we don't have the exact answer to.

Personally I feel that knowing we still have roughly $65m-$70m left for P3, I feel pretty good about this. It keeps a lot of irons in the fire while preserving the bulk of our funds for Otena for P3. I think that puts us into an even better negotiating position for big pharma because it shows we could potentially strike gold with our other candidates and we aren't resting on our laurels with just one drug.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities